English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
“天然分子” 的葫芦里,给慢病埋的什么药?
Mar 03, 2023 09:47 HKT
亿胜生物与复宏汉霖签订治疗年龄相关性黄斑变性全球共同开发及独家许可协议之经修订协议
Feb 22, 2023 18:50 HKT
億勝生物與復宏漢霖簽訂治療年齡相關性黃斑變性全球共同開發及獨家許可協議之經修訂協議
Feb 22, 2023 18:49 HKT
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Feb 22, 2023 18:48 HKT
疫苗开发不断变化的全球格局:Novotech 和 Endpoints News 网络研讨会
Feb 16, 2023 08:00 HKT
疫苗開發不斷變化的全球格局:Novotech 和 Endpoints News 網絡研討會
Feb 16, 2023 08:00 HKT
백신 개발 발전의 글로벌 환경: 노보텍 및 엔드포인트 뉴스 웨비나
Feb 16, 2023 08:00 HKT
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
Feb 15, 2023 09:00 HKT
Novotech 全球报告:亚太地区稳健的 1 期试验增长
Feb 13, 2023 06:00 HKT
Novotech 全球報告:亞太地區穩健的 1 期試驗增長
Feb 13, 2023 06:00 HKT
노보텍 글로벌 보고서: 아시아 태평양 지역에서 1단계 임상시험의 확고한 성장
Feb 13, 2023 06:00 HKT
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
Feb 10, 2023 21:06 HKT
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
Feb 10, 2023 19:00 HKT
亚太地区细胞与基因研究:Novotech 的增长速度比世界其它地区快 50%
Feb 04, 2023 07:00 HKT
亞太地區細胞與基因研究:Novotech 的增長速度比世界其它地區快 50%
Feb 04, 2023 07:00 HKT
아시아 태평양 지역 세포유전자 연구: 노보텍이 세계의 나머지 모든 기관들보다 50% 더 빠르게 성장
Feb 04, 2023 07:00 HKT
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
Feb 03, 2023 13:00 HKT
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
Jan 12, 2023 15:00 HKT
Novotech Acquires European CRO, Strengthens Global Operations
Jan 12, 2023 15:00 HKT
Novotech 收购美国药物开发咨询公司 CBR International
Jan 12, 2023 15:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: